Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2017

16.10.2017 | Hepatobiliary Tumors

Comments to “Long-Term Survival Benefit and Potential for Cure After R1 Resection for Colorectal Liver Metastases”

verfasst von: Alessandro Cucchetti, MD, Matteo Cescon, MD, PhD, Valentina Bertuzzo, MD, Giorgio Ercolani, MD, PhD

Erschienen in: Annals of Surgical Oncology | Sonderheft 3/2017

Einloggen, um Zugang zu erhalten

Excerpt

We read with interest the article by Hosokawa et al. regarding what they called as “potentially cured” patients submitted to R1 resection of colorectal liver metastases (CLM).1 Authors defined “cure” as a disease-free interval of 5 years or more after the last hepatectomy or the last resection of extra-hepatic metastases. From an initial study population of 428 resected patients (R0: 219; R1: 209), they excluded 36.7% of patients with less than 5 years of follow-up and identified 271 patients for survival analyses (R0: 130; R1: 141). In this latter study group, 18% of initially R1 and 23% of R0 patients did not experience any further tumor recurrence. We believe that this measure can not be considered as a true “cure fraction”. In epidemiology, cure is said to occur when the mortality of patients, treated for a specific disease, returns to the same level as that of the general population, as endorsed by the United States National Cancer Institute.2 In the present analysis such a comparator was not provided and Authors empirically set the time-to-cure at 5 years from surgery. We recently reported what is the probability of being cured from CLM after R0 hepatic resection using a cure-rate model.3 We observed that in the whole study population (1012 patients) the time-to-cure was 6.5 years with a 99% level of confidence, meaning that after this time point, a patient alive without tumor recurrence could be considered cured with 99% certainty. The time-to-cure was found to increase up to more than 7 years in presence of negative prognostic factors. Thus, from this point of view the threshold of 5 year has to be considered too early in respect to the history of the cancer. If not statistically assessed, the “safety” threshold to define “cure” must be moved toward, even up to 10 years, as already adopted by other Authors.4,5 In the view of all these aspects, the present definition of “cure” seems misleading and can lead to inaccurate informations to patients who would like to be fully informed regarding what awaits them after hepatic surgery.3 On the contrary, we believe that the measure that Authors provided in their article has to be considered as a “conditional survival” that is, in the present study, the probability of being alive without tumor recurrence once that 5 years from after the last hepatectomy or the last resection of extra-hepatic metastases have already passed.6,7
Literatur
1.
Zurück zum Zitat Hosokawa I, Allard MA, Gelli M, et al. Long-term survival benefit and potential for cure after R1 resection for colorectal liver metastases. Ann Surg Oncol. 2016;23:1897–905CrossRefPubMed Hosokawa I, Allard MA, Gelli M, et al. Long-term survival benefit and potential for cure after R1 resection for colorectal liver metastases. Ann Surg Oncol. 2016;23:1897–905CrossRefPubMed
3.
Zurück zum Zitat Cucchetti A, Ferrero A, Cescon M, et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2015;22:1908–14.CrossRefPubMed Cucchetti A, Ferrero A, Cescon M, et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2015;22:1908–14.CrossRefPubMed
4.
Zurück zum Zitat Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–80.CrossRefPubMed Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–80.CrossRefPubMed
5.
Zurück zum Zitat Pulitanò C, Castillo F, Aldrighetti L, et al. What defines ‘‘cure’’ after liver resection for colorectal metastases? Results after 10 years of follow-up. HPB (Oxford). 2010;12:244–9.CrossRefPubMedPubMedCentral Pulitanò C, Castillo F, Aldrighetti L, et al. What defines ‘‘cure’’ after liver resection for colorectal metastases? Results after 10 years of follow-up. HPB (Oxford). 2010;12:244–9.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Tan MC, Butte JM, Gonen M, et al. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. HPB (Oxford). 2013;15(10):803–13.CrossRefPubMedPubMedCentral Tan MC, Butte JM, Gonen M, et al. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. HPB (Oxford). 2013;15(10):803–13.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Hieke S, Kleber M, König C, Engelhardt M, Schumacher M. Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res. 2015;21:1530–6.CrossRefPubMed Hieke S, Kleber M, König C, Engelhardt M, Schumacher M. Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res. 2015;21:1530–6.CrossRefPubMed
Metadaten
Titel
Comments to “Long-Term Survival Benefit and Potential for Cure After R1 Resection for Colorectal Liver Metastases”
verfasst von
Alessandro Cucchetti, MD
Matteo Cescon, MD, PhD
Valentina Bertuzzo, MD
Giorgio Ercolani, MD, PhD
Publikationsdatum
16.10.2017
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe Sonderheft 3/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6121-y

Weitere Artikel der Sonderheft 3/2017

Annals of Surgical Oncology 3/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.